This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA's Endocrinologic and Metabolic Drugs Advisory Committee will review the recombinant parathyroid hormone Forteo (teriparatide) on July 27 for treatment of osteoporosis
You may also be interested in...
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.